Pfizer Inc. (PFE) Shares Sold by Lombard Odier Asset Management Europe Ltd

Lombard Odier Asset Management Europe Ltd lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 65,491 shares of the biopharmaceutical company’s stock after selling 2,130 shares during the quarter. Lombard Odier Asset Management Europe Ltd’s holdings in Pfizer were worth $2,372,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in PFE. BlackRock Inc. grew its position in shares of Pfizer by 2.8% during the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock worth $16,398,445,000 after acquiring an additional 12,183,218 shares during the last quarter. Mackenzie Financial Corp grew its position in shares of Pfizer by 29,164.7% during the fourth quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company’s stock worth $415,878,000 after acquiring an additional 11,442,753 shares during the last quarter. Bank of New York Mellon Corp grew its position in Pfizer by 11.9% in the 4th quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock valued at $2,562,162,000 after buying an additional 7,534,957 shares during the last quarter. Stifel Financial Corp grew its position in Pfizer by 5,413.5% in the 3rd quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock valued at $262,515,000 after buying an additional 7,226,697 shares during the last quarter. Finally, American Century Companies Inc. grew its position in Pfizer by 46.6% in the 4th quarter. American Century Companies Inc. now owns 22,539,888 shares of the biopharmaceutical company’s stock valued at $816,395,000 after buying an additional 7,161,892 shares during the last quarter. 69.53% of the stock is currently owned by institutional investors.

PFE has been the topic of a number of analyst reports. Sanford C. Bernstein set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, January 30th. BMO Capital Markets set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, February 15th. SunTrust Banks reiterated a “hold” rating and issued a $40.00 price objective (up from $33.00) on shares of Pfizer in a research report on Monday, January 29th. Finally, Barclays lifted their price objective on shares of Pfizer from $38.00 to $41.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $40.08.

Shares of Pfizer opened at $35.68 on Friday, according to MarketBeat Ratings. The firm has a market cap of $213.65 billion, a price-to-earnings ratio of 13.46, a P/E/G ratio of 1.78 and a beta of 0.89. Pfizer Inc. has a one year low of $31.67 and a one year high of $39.43. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.98 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.74 by $0.03. The company had revenue of $12.91 billion for the quarter, compared to analyst estimates of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The business’s revenue was up 1.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.69 EPS. analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.81%. The ex-dividend date is Thursday, May 10th. Pfizer’s dividend payout ratio (DPR) is presently 51.32%.

In other news, CEO Ian C. Read sold 132,312 shares of Pfizer stock in a transaction on Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total transaction of $4,764,555.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Charles H. Hill sold 42,393 shares of Pfizer stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total value of $1,515,973.68. The disclosure for this sale can be found here. Insiders have sold a total of 380,349 shares of company stock valued at $13,829,340 in the last ninety days. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply